Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
J Med Radiat Sci ; 69(3): 277-278, 2022 Sep.
Article in English | MEDLINE | ID: covidwho-2013589

ABSTRACT

Benefit of telehealth goes beyond providing consultations. Telehealth can be used to enhance rural workforce capabilities and scope of practice as part of strengthening rural health systems.


Subject(s)
Rural Health Services , Telemedicine , Humans , Referral and Consultation , Rural Health , Rural Population
2.
Asia Pac J Clin Oncol ; 18(6): 650-659, 2022 Dec.
Article in English | MEDLINE | ID: covidwho-1662228

ABSTRACT

INTRODUCTION: The Australasian Teletrial Model was piloted in co-funded sites across Australia. The purpose was to extend the reach of clinical trials using telemedicine to improve equity and access to this treatment pathway for oncology patients. Experts across Australia gathered to share the learnings of implementation so that future directions can be effective and sustainable. METHODS: The 1-day workshop was attended in person and virtually. Attendees were invited to analyze and disseminate the results. Recordings from the presentations were coded independently by three researchers and synthesized. The results were sent to the authorship team for further review to build consensus on the findings in three drafts. RESULTS: Four key themes were identified: "Being on the Same Page," "Building Foundations," "Key Roles in Teletrials," and "Incentives." Although there were many successes that were accelerated by the COVID-19 pandemic, there is work still to be done. CONCLUSION: The Australasian Teletrial Model has been identified as acceptable and feasible. Future directions need to continue to work on streamlining regulatory processes, implementation and monitoring, and build knowledge to further build networks across Australia.


Subject(s)
COVID-19 , Neoplasms , Humans , Australia , Medical Oncology , Neoplasms/therapy , Pandemics , Congresses as Topic , Societies, Medical
3.
JCO Oncol Pract ; 16(8): 467-482, 2020 08.
Article in English | MEDLINE | ID: covidwho-254275

ABSTRACT

Cancer has become a prevalent disease, affecting millions of new patients globally each year. The COVID-19 pandemic is having far-reaching impacts around the world, causing substantial disruptions to health and health care systems that are likely to last for a prolonged period. Early data have suggested that having cancer is a significant risk factor for mortality from severe COVID-19. A diverse group of medical oncologists met to formulate detailed practical advice on systemic anticancer treatments during this crisis. In the context of broad principles, issues including risks of treatment, principles of prioritizing resources, treatment of elderly patients, and psychosocial impact are discussed. Detailed treatment advice and options are given at a tumor stream level. We must maintain care for patients with cancer as best we can and recognize that COVID-19 poses a significant competing risk for death that changes conventional treatment paradigms.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/mortality , Medical Oncology , Neoplasms/mortality , Pneumonia, Viral/mortality , COVID-19 , Coronavirus Infections/complications , Coronavirus Infections/therapy , Coronavirus Infections/virology , Delivery of Health Care , Humans , Neoplasms/complications , Neoplasms/therapy , Neoplasms/virology , Pandemics , Pneumonia, Viral/complications , Pneumonia, Viral/therapy , Pneumonia, Viral/virology , Risk Factors , SARS-CoV-2 , Telemedicine
SELECTION OF CITATIONS
SEARCH DETAIL